CTOs on the Move

Emendo Biotherapeutics

www.emendobio.com

 
Emendo biotherapeutics develops next generation gene editing tools for genetic disorders, addressing the current technological gaps for realizing the promise of gene therapy.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Emendo Biotherapeutics raised $61M on 01/15/2020

Similar Companies

Ambrilia Biopharma

Ambrilia Biopharma Inc. is a Verdun, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Lakemary

Founded in 1969, Lakemary is in America’s Heartland. Our main campus and ranch are on 32 acres in the quiet town of Paola, KS just south of Kansas City. Our...

Clinigen Group

Clinigen Group plc is a United Kingdom-based pharmaceutical and services company. The Companys principal activities include management, sale and distribution of pharmaceutical products, which have associated expiry dates. The Company operates through ...

InforMed Direct

InforMed Direct is a Haddam, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Immunic

Immunic, Inc. (Nasdaq: IMUX) is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. The company is developing three small molecule products: its lead development program, IMU-838, a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH and exhibits a host-based antiviral effect, is currently being developed as a treatment option for multiple sclerosis, ulcerative colitis, Crohn`s disease, and primary sclerosing cholangitis. IMU-935, a selective inverse agonist of the transcription factor RORγt, is targeted for development in psoriasis and Guillain-Barré syndrome. IMU-856, which targets the restoration of the intestinal barrier function, is targeted for development in diseases involving bowel barrier dysfunction.